Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. Issue 1 (19th October 2017)

• Record Type: Journal Article
• Authors: Gaksch, Lukas; Kashofer, Karl; Heitzer, Ellen; Quehenberger, Franz; Daga, Shruti; Hofer, Sybille; Halbwedl, Iris; Graf, Ricarda; Krisper, Nina; Hoefler, Gerald; Zebisch, Armin; Sill, Heinz; Wölfler, Albert
• Is Part Of: American journal of hematology. Volume 93:Issue 1(2018:Jan.)
• Page Start: 23
• Page End: 30
• Publication Date: 2017-10-19
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24922
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Despite achieving complete remission after intensive therapy, most patients with cytogenetically normal (CN) AML relapse due to the persistence of submicroscopic residual disease. In this pilot study, we hypothesized that detection of leukemia‐specific mutations following consolidation treatment using a targeted parallel sequencing approach predicts relapse. We included 34 AML patients of whom diagnostic material and remission bone marrow slides after at least one cycle of consolidation were available. Isolated DNA was screened for mutations in 19 genes using an Ion Torrent sequencing platform. Furthermore, the variant allelic frequency of distinct mutations was validated by digital PCR and sequencing using a barcoding approach. Twenty‐seven out of 34 patients could be analyzed for mutation clearance. We identified 68 somatic mutations at diagnosis (median, 3 mutations per patient; range 1‐5) and 22 of these were still detected in 16 patients after consolidation therapy with a reliable sensitivity of 0.5% (median, 1 mutation; range 0‐3). The most frequent noncleared mutations were found in DNMT3A . However, as persistence of these mutations has recently been shown to be without any impact on relapse risk, we performed survival and relapse risk analysis excluding DNMT3A mutations. Importantly, persistence of non‐ DNMT3A mutations was associated with a higher risk of AML relapse (7/8 pts versus 6/19 pts; P = .013) and with a shorter relapse‐free survival (333 days vs. not reached; log‐rank P = .0219). Detection of residual disease by routine targeted parallel sequencing proved feasible and effective as persistence of somatic mutations other than DNMT3A were prognostic for relapse in CN AML.